Related Experiment Video
Updated: Aug 24, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
B lymphocyte depletion therapy with rituximab in rheumatoid arthritis
J C W Edwards1, M J Leandro, G Cambridge
1Centre for Rheumatology, Arthur Stanley House, University College London, 40-50 Tottenham Street, London W1T 4NJ, UK. jo.edwards@ucl.ac.uk
Abstract:
B lymphocyte depletion therapy in rheumatoid arthritis can provide major clinical benefits. Widespread use in the future will depend on continued evidence of safety, particularly in the context of long term use. Rituximab is a highly effective agent, but it may be best used in combination with other agents. Substantial improvement following a single course of therapy has been found to last up to 42 months, and it is reasonable to hope that further development of strategies targeting B cells will extend this toward the original aim of truly long-term remission.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF